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as by eliciting anti-inflammatory responses [1, 2] . However, other data have shown that the effectiveness of RT is also related to the "quality" of the RT-induced tumor cell death. It has been shown that, under some circumstances, local RT triggers an immunogenic cell death (ICD) that is able to eradicate established distant tumors through the generation of tumor-specific cytotoxic CD8 + T cells [3] . The ICD, which is a "good death" for tumor immunogenicity, can enhance both the priming and the effector phase of the anti-tumor immune response, and it is mainly mediated by damage-associated molecular patterns (DAMPs) that include surface-exposed calreticulin (CRT) [4] and ERP57 [5, 6] , ATP secretion that activates the NLRP3 inflammasome in dendritic cells (DCs) [7] , and the secretion of high mobility group protein B1 (HMGB1) [8] . In addition, this antigen-specific T-cell immunity was TLR4 dependent as RT could not lead to the rejection of inoculated live tumors in the TLR4 −/− mice, whereas it did so in the wild-type mice [9] . The effectiveness of RT was suppressed in immunodeficient mice or after the depletion of CD8 + or CD4 + T cells [4] .
Moreover, RT seems to impact multiple aspects of antitumor immunity, such as priming and effector phases, and of crosstalk between the immune system and the tumor [10] . In particular, low-dose irradiation induces macrophage differentiation to an iNOS + /M1 phenotype, which is a key element in eliciting effective T-cell immunotherapy [11] . More remarkably, the depletion of Treg significantly ameliorates the outcome of RT, mainly through the enhancement of radiation-mediated anti-tumor immunity [12] .
Recently, the occurrence of ICD has been reported in cancer patients. Interestingly, the majority of ICD characteristics, such as tumor antigen-specific T-cell responses, elevated serum levels of HMGB1 and the expression of cell surface CRT, have been documented in patients with esophageal squamous cell carcinoma (ESCC) after RT [13] . More interestingly, the level of secreted HMGB1 was correlated with patient survival and clinic outcomes [13] .
The "abscopal effect"
In rare cases, spontaneous regressions of tumors or metastases that were not included in the radiation field have been reported. This type of distant effect was qualified historically as the "abscopal effect". This systemic effect has been reported clinically in multiple cancer types, such as hepatocellular carcinoma [14, 15] , chronic lymphocytic leukemia [16] , renal cell carcinoma [17] , malignant lymphomas [18] and melanomas [19, 20] , and, in patients treated concomitantly with RT and granulocyte-macrophage colony-stimulating factor; objective abscopal responses were observed in some patients with metastatic solid tumors [21] . Moreover, another report suggests that in some advanced melanoma patients who were given RT after progression under ipilimumab, the abscopal effect was observed, which was associated with prolonged survival [22] .
There has been a very promising report that concomitant RT with the blockade of CTLA-4 was able to elicit an abscopal effect in mouse models [23] . Similar distant effects have been frequently described in many mouse models of tumor after local RT [24] [25] [26] without the successful determination of the exact molecular and cellular mechanisms behind them, although some speculations have been made about the implication of immune mediation [27] . Overall, despite this missing information, accumulating scientific evidence underlines the ability of local RTinduced immuno-modulation to trigger a systemic immune reaction.
Why does such a phenomenon occur rarely in cancer patients?
Why does the "abscopal effect" occur rarely in patients treated with RT and why does RT not result in tumor rejection more often? It is likely that one of the main reasons is due to the highly immunosuppressive tumor microenvironment of well-established tumors that constantly antagonizes the anti-tumor immune responses that are triggered by RT. In this situation, additional or combinatorial immunotherapy may be needed to overcome the immunosuppressive networks and, therefore, enhance the systemic immune impact of RT.
The main challenge of such a combinatorial therapy is to find the appropriate immunotherapy (IT) that is most synergistic with RT In general, IT could be directed to target one or multiple steps of the immune activation pathway. In particular, the following steps can be targeted: DC presentation and T-cell priming, T-cell activation and anti-tumor effector functions, T-cell differentiation into memory T cells, and tumor microenvironment antagonism. As far as we know, many negative regulatory molecules are expressed on the surface of activated T cells. The essential role of these regulatory molecules is to avoid auto-immune complications through an over-activation of T cells. Many such molecules, called immune checkpoints, exist such as CTLA4 (cytotoxic T lymphocyte-associated antigen 4) and programmed cell death protein 1 (PD1).
In the preclinical setting, the association of RT and immunotherapy has shown encouraging signs of synergistic improvements in different tumor models. Radio-immunotherapy with PD1 blockade induced an increase in the secretion of TNF-α by CD8
+ T cells and the suppression of MDSCs, and consequently caused a decrease in tumor volume [28] , higher TILs and lower Treg densities with higher survival rates in a glioblastoma model [29] . In addition, radio-immunotherapy with CTLA4 blockade induced lower Treg densities and higher T-cell receptor diversity [30] . Interestingly, adding RT to autologous T-cell infusion induced long lasting remission and improved survival [31] .
An excellent clinical outcome was obtained with immune checkpoint inhibitors such as in patients with metastatic melanoma after CTLA-4 inhibition by ipilimumab [32] or in many others cancers types after the inhibition of PD-1 by nivolumab where the tumors shrank by about half or more in 31% of melanoma, 29% of kidney cancer and 17% of lung cancer patients [33, 34] . The benefit was additive when a combination of nivolumab and ipilimumab was administered in patients with advanced melanoma, and at least 53% of patients had an objective response, all with tumor reduction of 80% or more [35] ; similar to NSCLC lung cancer patients, a 1-year overall survival rate was observed in 69% of the patients [36] . Even in more aggressive lung cancer, such as recurrent SCLC, combination IT conferred an objective response in 42% of patients compared with the 10% obtained with nivolumab alone [37] . Other immune checkpoint inhibitors showed similar benefits in their outcomes and safety profiles, such as the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab [38] .
Altogether, these clinical data showing combination benefits in different cancer types suggest that combination or sequential immunotherapies that target distinct immune pathways may be an effective strategy with the potential to further enhance the magnitude of the anti-tumor immune response over single agents.
In spite of these outstanding advantages, an important limitation of immune checkpoint inhibitor-based IT is the small proportion of patients who achieve a complete clinical response. Similar limitations have been observed with dendritic cell (DC) activation-based IT [39] .
Thus, these IT strategies may not be completely effective in overcoming the immunosuppressive networks that are associated with the tumor. Consequently, there is a critical need to develop more potent immunotherapies. This may be achieved by therapies that decrease the tumorderived immunosuppression. Tumors deploy very complex immunosuppressive mechanisms that act at each of the steps required for immune activation. Principally, this occurs through the secretion of suppressive molecules, such as the inhibitory cytokines IL-10 and transforming growth factor-β (TGF-β), the presence of regulatory lymphocytes (Treg) or myeloid-derived suppressor cells (MDSCs), and many other mechanisms [40] .
In situ tumor vaccination: IL-12-based TH1 immunotherapy combined with RT
Ideally, the optimal IT will be one that will dampen many levels of the tumor-associated immunosuppression. One of the rare candidates with such an ability is interleukin-12 (IL-12). Because it is polyvalent and one of the rare cytokines connecting innate and adaptive immunity, it can co-activate both NK cells and cytotoxic CD8 + T lymphocytes. IL-12 is a major factor in tumor rejection by polarizing the naive CD4
+ helper T cells toward the T helper-1 (TH1) phenotype. In addition, IL-12 can modulate the anti-tumor response at different levels: by increasing antigen presentation through IFN-ɣ secretion and leading to MHC class I/II upregulation and by improving cellular immunity through boosting both the proliferation of cytotoxic CD8
+ T and NK cells as well as their cytolytic activity [41] . Moreover, a radiosensitizing effect of combined IR and IL-12 treatment has already been demonstrated that probably incorporates long term immune memory, as the cured animals were resistant to secondary challenge. The work indirectly implied a possible abscopal effect of the treatment combination [42] .
After the excellent results obtained in animal models, there have been multiple clinical trials aimed at evaluating systemic recombinant IL-12 in cancer patients. Unfortunately, the clinical outcomes were very modest and often accompanied with unacceptable levels of adverse events, which tempered the enthusiasm for the use of this recombinant cytokine in patients. In fact, only a few studies reported promising results with recombinant IL-12. After a meticulous analysis of all these clinical studies, we and other teams have noted that the major limiting factor was the low levels of IL-12 infiltrating into the tumor even in patients with high IL-12 exposure and toxicities. In contrast, in tumor biopsies of the few cases of objective complete responses obtained for patients with Kaposi's sarcoma and B-cell non-Hodgkin lymphoma, notable tumor levels of IL-12 were detected.
Recently, we showed that IL-12 is the main mediator of the Immunogenic Cell Death. The depletion of IL-12 abolished the immunity mediated by RT. Local RT combined with local IL-12-based TH1 therapy triggers a massive reduction of CT26 colon cancer cells in tumor-bearing mice (Fig. 1a) , glioblastoma, melanoma, lung cancer, and castration-resistant prostate cancer (Obeid et al., in preparation). Moreover, this in situ vaccination and combinatorial approach conferred a longer survival of mice with CT26 colon cancer compared to mice treated with RT or intratumoral IL-12 alone (Fig. 1b.) Our preliminary results showed that this radio-immunotherapy combination mediates tumor immuno-modulation that causes a systemic anti-tumor response through the augmentation of TILs 1 3
(tumor-infiltrating lymphocytes) (Fig. 2) . These results confirmed a powerful synergy between local RT and local IL-12-based immunotherapy by promoting anti-tumor immunity of T cells to overcome tumor-derived immunosuppression in a highly immunosuppressive cancer such as glioblastoma (GB), among others (Fig. 2) . GB is an incurable cancer and one of the most aggressive cancers known because of the high tumor-associated immunosuppressive microenvironment. An existing study reported that intratumoral IL-12 therapy combined with CTLA-4 inhibitioninduced T-cell-mediated glioma rejection [43] .
Therefore, we believe that IL-12 remains a very promising candidate for tumor immunotherapy, but the systemic administration strategy should be undoubtedly replaced by a tumortargeting approach to maximize efficacy by increasing IL-12 expression in the tumors while improving the safety profile by reducing systemic exposure. Hence, an IL-12-targeted tumor-delivery system is required that will allow an acceptable safety profile and a stronger dampening of the tumorassociated immunosuppressive microenvironment. Recently, several IL-12-based therapies with intratumoral/local delivery systems have been evaluated clinically. There are three pilot strategies: the first is based on intratumoral delivery of the IL-12 gene by electroporation [44, 45] , the second is based on intratumoral injections of IL-12-expressing adenovirus vector in combination with oral activator ligand [46] , and the third is based on intralesional administration of IL-12 combined with the human monoclonal antibody fragment L19 [47] .
The first two approaches showed excellent safety profiles during phase I trials, and the recently updated phase II interim data show very promising results with the IL-12-expressing adenovirus vector. In fact, 78 and 45% of the treated lesions resulted in a durable response at 3 and 6 months, respectively. Biopsies of the injected lesions showed necrotic areas and lymphocyte infiltrations [44] . The electroporationbased DNA approach showed a robust response and better performance in comparative studies with high and long lasting levels of serum IL-12. The results from the third targeting approach were very encouraging as well, with the detection of systemic activity of IL-12 following intralesional immuno-stimulatory treatment. In fact, 7/13 (53.8%) of the non-injected lesions in patients with stage IIIC and IVM1a metastatic melanoma exhibited a complete response. Accordingly, the intralesional administration of L19-IL2 and L19-TNF may represent an effective method for the local control of inoperable melanoma lesions.
Optimistically, a nice proof of concept report has shown that the combination of local ablative techniques with peritumoral IL-2 gene therapy is effective [48] . In fact, in dogs with mastocytoma, the rate of complete response (CR) to electrochemotherapy combined with peritumoral IL-12 electrotransfer was increased to 72% of all the treated tumors and even to 100% in tumors smaller than 2 cm 3 . Very interestingly, some very large tumors (10 cm 3 ) were also cured and the authors reported the absence of recurrence over a very long period of at least 40 months. These data clearly show the benefit of combining intratumoral IL-12 therapy with the conventional treatment. The appropriate delivery strategy may depend on the clinical situation as well as the tumor depth and the topography.
The relevance and potential contribution of a combinatorial approach to cancer treatment
The last 3 years have marked a turning point in cancer immunotherapy. We have experienced complete 5 cells) were established in 6-weekold female BALB/c mice, as described previously [6] ). The intratumoral administration of IL-12 was delivered at 10 µg/day for a period of 7 days, in the presence or absence of radiotherapy (RT) delivered to the tumor site at 2 Gy/day for a period of 7 days only. a Tumors treated concomitantly with IL-12 and RT were significantly smaller (Student's t test; P < 0.001) than untreated tumors (treated with PBS, co) or those treated with either IL-12 or RT alone. b Mice treated concomitantly with IL-12 and RT survived longer than the untreated mice (co) or those treated with IL-12 or RT alone, as shown by a Kaplan-Meier survival plot (n = 14 animals/group; P < 0.05, logrank test) remission in metastatic melanoma patients and excellent clinical responses in many other advanced cancers. Unfortunately, this "breakthrough" was not observed in all patients, as many of them experienced a low or no clinical response. The reason for these discrepancies is not well understood, but accumulating evidence suggests that one of the major impediments could be the "powerful" immunosuppressive tumor microenvironment.
Tumor-derived immunosuppression constantly alienates anti-tumor immune responses, and accordingly, immunotherapies that are optimally designed to reverse this solid network need to overcome the tumor-derived immunosuppression and provide benefits for the cancer treatment.
Targeted IL-12-based TH1 therapy offers great promise for both boosting immune responses and dampening immunosuppression. IL-12 is a master regulator of Fig. 2 Generation of a potent anti-tumor immune response by an in situ vaccination approach that combines local radiotherapy and intratumoral IL-12-based immunotherapy. Antagonizing the immunosuppressive microenvironment in the tumors with IL-12 substantially increases the immune reaction generated by ICD-induced RT. The tumor immuno-modulation by RT is a very complex process and goes through multiple steps. The tumor ICD exposes an "eat-me signal", such as CRT, which is a required step for the phagocytosis by DCs. The phagocytosis of ICD by DCs is accompanied by the release of other mediators such as the HMGB1 that is required for DC maturation and consequently for cross presentation into the draining lymph nodes and generation of tumor-specific effector T cells. In wellestablished tumors, the cytotoxic CD8 + T-cell response generated by RT is not enough to overcome the immunosuppressive nature of the tumor and consequently to reject the tumors. One of the possible solutions is to dampen the immunosuppressive microenvironment in the tumors by bridging innate and adaptive immunity. IL-12 is a multifunctional cytokine. IL-12 can act in many levels of the tumorassociated immunosuppressive network. IL-12 directly activates both NK cells and cytotoxic-T cells, which can cause high levels of IFN-ɣ secretion and TH1 polarization, two crucial steps for the generation of potent anti-tumor immunity. IL-12 can also cause macrophages to produce several anti-angiogenic cytokines such as CXCL9 and CXCL10. By inducing the upregulation of MHC I and MHC II, IL-12 enhances cross presentation, which is an essential step for eliciting a strong anti-tumor immune response. IL-12 is able to reprogram the immune suppressor cells of the tumor stroma, including regulatory T cells, immature dendritic cells, and myeloid-derived suppressor cells (MDSCs). Reversing the dysfunction of these cells is required to stimulate tumor-specific T cells, as shown in a preclinical model [49] . Specifically, the immunosuppressive environment will be converted from a T H 2-dominated environment to a more T H 1-like response with reduced IL-4 and IL-5 levels. Thus, this radio-immunotherapy (RIT) in situ tumor vaccination protocol, which combines RT with IL-12-based T H 1 immunotherapy, allows for a strong synergy and is able to generate potent anti-tumor immunity adaptive TH1 cell-mediated immunity. Optimally boosting tumor IL-12 with a targeted strategy will impact the tumor environment in at least three ways: by improving the T-cell cytotoxic activity, by activating and recruiting innate immune cells, and by re-programming the stromaassociated immune suppressor cells. The second main rationale for this local-immune intervention is to avoid the toxic effects of systemic IL-12 administration.
Undeniably, combined immunotherapy with the conventional treatment results in a potent synergy that may significantly improve the clinical outcomes. Our results and many recent reports support the fact that local immuno-modulation by radiation therapy can synergize with immunotherapy to promote systemic anti-tumor immunity, leading to the spontaneous regression of tumors and metastases that are outside the radiation field. This radio-immunotherapy approach may bring new hope for patients with very limited therapeutic options, especially for brain tumors and for tumors deep within the body.
